Trial reportBMC infectious diseases2018
Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol.
Trial report in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02840877 (The Impact of Alcohol Consumption on Tuberculosis Treatment Outcomes), which is not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Alcohol Consumption on Tuberculosis Treatment Outcomes
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Impact of alcohol consumption, substance use, and smoking on treatment outcomes in tuberculosis: a systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Time to sputum culture conversion and its associated factors among drug-resistant tuberculosis patients: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis.Alcoholism, clinical and experimental research · 2021Pooled it
- The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020Pooled it
- Within-host pathogen population diversity predicts treatment response in Tuberculosis.medRxiv : the preprint server for health sciences · 2026Article
- Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Convolutional neural networks quantify antibiotic resistance in Mycobacterium tuberculosis with diagnostic grade accuracy and predict treatment response.Nature communications · 2026Article
- Treatment outcomes among tuberculosis patients with co-morbidities at Ghana's premier national referral centre: a retrospective cross-sectional study.BMC infectious diseases · 2026Article
- Linkage to TB and HIV care for persons who smoke illicit drugs: a prospective cohort study.IJTLD open · 2026Article
- Factors associated with unsuccessful treatment outcomes among drug-resistant tuberculosis patients in Loreto, Peru, 2015-2023: A retrospective cohort study.PLOS global public health · 2026Article
- "They Call Us Amaphara (Junkies)": Intersectional Tuberculosis, Alcohol, and Drug Stigma in South Africa.Stigma and health · 2025Article
- An Integrated Data-Driven Model for Clinical Phenotyping of Tuberculosis Disease Severity.medRxiv : the preprint server for health sciences · 2025Article
- Contamination rates in serially sampled sputum specimens obtained during tuberculosis treatment to capture culture conversion.Microbiology spectrum · 2025Article
- Risk factors for tuberculosis treatment outcomes: a statistical learning-based exploration using the SINAN database with incomplete observations.BMC medical informatics and decision making · 2025Article
- Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Tuberculosis treatment failure: what are the risk factors? A comprehensive literature review.Multidisciplinary respiratory medicine · 2025Article
- A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling.CPT: pharmacometrics & systems pharmacology · 2025Article
- Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk.The American journal of gastroenterology · 2024Article
- Understanding the impact of pandemics on long-term medication adherence: directly observed therapy in a tuberculosis treatment cohort pre- and post-COVID-19 lockdowns.BMC infectious diseases · 2024Observational
- Patient and provider perceptions of the relationship between alcohol use and TB and readiness for treatment: a qualitative study in South Africa.BMC public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundAn estimated 10% of tuberculosis (TB) deaths are attributable to problematic alcohol use globally, however the causal pathways through which problem alcohol use has an impact on TB treatment outcome is not clear. This study aims to improve understanding of these mechanisms. Specifically, we aim to 1) assess whether poor TB treatment outcomes, measured as delayed time-to-culture conversion, are associated with problem alcohol use after controlling for non-adherence to TB pharmacotherapy; and 2) to determine whether pharmacokinetic (PK) changes in those with problem alcohol use are associated with delayed culture conversion, higher treatment failure/relapse rates or with increased toxicity.
methodsOur longitudinal, repeated measures, prospective cohort study aims to examine the associations between problem alcohol use and TB treatment outcomes and to evaluate the effect of alcohol on the PK and pharmacodynamics (PD) of TB drugs. We will recruit 438 microbiologically confirmed, pulmonary TB patients with evidence of rifampicin susceptibility in Worcester, South Africa with 200 HIV uninfected patients co-enrolled in the PK aim. Participants are followed for the six months of TB treatment and an additional 12 months thereafter, with sputum collected weekly for the first 12 weeks of treatment, alcohol consumption measures repeated monthly in concert with an alcohol biomarker (phosphatidylethanol) measurement at baseline, and in person directly observed therapy (DOT) using real-time mobile phone-based adherence monitoring. The primary outcome is based on time to culture conversion with the second objective to compare PK of first line TB therapy in those with and without problem alcohol use. DISCUSSION: Globally, an urgent need exists to identify modifiable drivers of poor TB treatment outcomes. There is a critical need for more effective TB treatment strategies for patients with a history of problem alcohol use. However, it is not known whether poor treatment outcomes in alcohol using patients are solely attributable to noncompliance. This study will attempt to answer this question and provide guidance for future TB intervention trials.
trial registrationClinicaltrials.gov Registration Number: NCT02840877 . Registered on 19 July 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.